: A Randomized, Phase 3, open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Platinum-Based Doublet Chemotherapy, and Ipilimumab (ANTI-CTLA-4 Antibody), Versus Pembrolizumab Monotherapy in First-line treatment of patients with Advanced or metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 equals to or greater than 50%
